Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4

  • P. A. Kelly
  • H. Wang
  • K. L. Napoli
  • B. D. Kahan
  • H. W. Strobel
Article

Summary

The ability of P450 3A9 to transform cyclosporine was studied and compared to that of human P450 3A4. Purified P450 3A4 and P450 3A9 proteins were reconstituted in a system containing potassium phosphate buffer, lipids, NADPH-P450 reductase, and glutathione with NADPH added to initiate the reaction. Cyclosporine was added alone and with or without the inhibitors, ketoconazole or troleandomycin. High performance liquid chromatography with ultraviolet (HPLC/UV) techniques were used to analyze for cyclosporine metabolites. Both P450 3A4 and P450 3A9 transformed cyclosporine to three metabolites: AM1, AM9, and AM4n. P450 3A4 predominantly formed AM1 (63% of metabolites formed) while P450 3A9 formed AM4n (59% of metabolites formed). Ketoconazole (0.5 μM) completely inhibited P450 3A9 catalyzed formation of AM1 and AM9 and reduced AM4n formation to 28% of control. AM4n, AM1, and AM9 formation catalyzed by P450 3A4 was reduced to 50%, 30%, and 10% of control, respectively, by 0.5 μM ketoconazole. Troleandomycin (>10μM) inhibited the formation of AM4n by P450 3A4 and P450 3A9 to 60–70% of control, while the production of AM1 by P450 3A4 was increased to 120% of control and the production of AM1 by P450 3A9 was inhibited to 50% of control. Inhibition of P450 3A4 by troleandomycin (>10 μM) reduced the formation of AM9 to 40% of control, but only reduced P450 3A9 formation of AM9 to 80% of control. This study shows that rat P450 3A9 is capable of transforming cyclosporine to multiple metabolites similar to those generated by human P450 3A4.

Keywords

Cytochrome P450 drug metabolism cyclosporine cytochrome P450 3A4 cytochrome P450 3A9 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Consensus Document. (1990): Hawk’s Cay Meeting on Therapeutic Drug Monitoring of cyclosporine. Transplant Proc., 22, 1357–1361.Google Scholar
  2. 2.
    Maurer G., Loosli H.R., Schreier E., Keller B. (1984): Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drug Metab. Dispos., 12, 120–127.PubMedGoogle Scholar
  3. 3.
    Kronbach T., Fischer V., Meyer U.A. (1988): Cyclosporine metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther., 43, 630–635.PubMedGoogle Scholar
  4. 4.
    Combalbert J., Fabre I., Fabre G. et al. (1989): Metabolism of cyclosporine A. IV. Purification and identification of rifampicin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P-450 IIIA gene subfamily. Drug Metab. Dispos., 17, 197–207.PubMedGoogle Scholar
  5. 5.
    Waxman D.J., Dannan G.A., Guengerich F.P. (1985): Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isozymes. Biochemistry, 24, 4409–4417.CrossRefPubMedGoogle Scholar
  6. 6.
    Prueksaritanont T., Correia M.A., Rettie A.E., Swinney D.C., Thomas P.E., Benet L.Z. (1993): Cyclosporine metabolism by rat liver microsomes: evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metab. Dispos., 21, 730–737.PubMedGoogle Scholar
  7. 7.
    Wassef R., Cohen Z., Langer B. (1985): Pharmacokinetic profiles of cyclosporine in rats. Influence of route of administration and dosage. Transplantation, 40, 489–493.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang H., Strobel H.W. (1997): Regulation of P450 3A9 gene expression by estrogen and catalytic studies using cytochrome P450 3A9 expressed inEscherichia coli. Arch. Biochem. Biophys., 344, 365–372.CrossRefPubMedGoogle Scholar
  9. 9.
    White I.N., Muller-Eberhand U. (1977): Decreased liver cytochrome P-450 in rats caused by norethindrone or ethynyloestradiol. Biochem. J., 166, 57–64.PubMedGoogle Scholar
  10. 10.
    Pichard L., Fabre I., Fabre G. et al. (1990): Cyclosporine A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos., 18, 595–606.PubMedGoogle Scholar
  11. 11.
    Guengerich F.P. (1988): Oxidation of 17α-ethynyl estradiol by human liver cytochrome P-450. Mol. Pharmacol., 33, 500–508.PubMedGoogle Scholar
  12. 12.
    Dignam J.D., Strobel H.W. (1977): NADPH-cytochrome P-450 reductase from rat liver: purification by affinity chromatography and characterization. Biochemistry, 16, 1116–1123.CrossRefPubMedGoogle Scholar
  13. 13.
    Shimada T., Misono K.S., Guengerich F.P. (1986): Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J. Biol. Chem., 261, 909–921.PubMedGoogle Scholar
  14. 14.
    Henriesson S., Lindholm A., Aravoglou P. (1990): Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol. Toxicol., 66, 49–52.CrossRefGoogle Scholar
  15. 15.
    Vickers A.E., Fischer V., Conners S. et al. (1992): Cyclosporin A metabolism in human liver, kidney, and intestine slices: comparison to rat and dog slices and human cell lines. Drug Metab. Dispos., 20, 802–809.PubMedGoogle Scholar
  16. 16.
    Omar G., Whiting P.H., Hawksworth G.M., Humphrey M.J., Burke M.D. (1997): Ketoconazole and fluconazole inhibition of the metabolism of cyclosporine A by human liver in vitro. Ther. Drug Monit., 19, 436–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Lampen A., Christians U., Bader A., Hackbarth I., Sewing K.F. (1996): Drug interactions and interindividual variability of cyclosporine metabolism in the small intestine. Pharmacology, 52, 159–168.CrossRefPubMedGoogle Scholar
  18. 18.
    Gonzalez F.J., Song B.J., Hardwick J.P. (1986): Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. Mol. Cell. Biol., 6, 2969–2976.PubMedGoogle Scholar
  19. 19.
    Yamazoe Y., Shimada M., Murayama N., Kawano S., Kato R. (1986): The regulation by growth hormone of microsomal testosterone 6-beta hydroxylase in male rat liver. J. Biochem., 100, 1095–1097.PubMedGoogle Scholar
  20. 20.
    Shimada M., Nagata K., Murayama N., Yamazoe Y., Kato R. (1989): Role of growth hormone in modulating the constitutive and phenobarbital-induced levels of two P-450 (6) beta (testosterone 6-beta hydroxylase) mRNAs in rat livers. J. Biochem., 106, 1030–1034.PubMedGoogle Scholar
  21. 21.
    Ribeiro V., Lechner M.C. (1992): Cloning and characterization of a novel CYP3A1 allelic variant: analysis of CYP3A1 and CYP3A2 sex-hormone-dependent expression reveals that the CYP3A2 gene is regulated by testosterone. Arch. Biochem. Biophys., 293, 147–152.CrossRefPubMedGoogle Scholar
  22. 22.
    Schenkman J.B., Greim H. (deds) Cytochrome P450: Hand book of Experimental Pharmacology. vol. 105. Berlin: Springer.Google Scholar
  23. 23.
    Prueksaritanont T., Hoener B.A., Benet L.Z. (1992): Effects of low-density lipoprotein and ethinyl estradiol on cyclosporine metabolism in isolated rat liver perfusions. Drug Metab. Dispos., 20, 547–552.PubMedGoogle Scholar
  24. 24.
    Kahan B.D., Welsh M., Schoenberg L. et al. (1996): Variable oral absorption of cyclosporine: a biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation, 62, 599–606.CrossRefPubMedGoogle Scholar
  25. 25.
    Seethalakshmi L., Flores C., Carboni A.A., Bala R., Diamond D.A., Menon M. (1990): Cyclosporine: its effects on testicular function and fertility in the prepubertal rat. J. Androl., 11, 17–24.PubMedGoogle Scholar
  26. 26.
    Sikka S.C., Bhasin S., Coy D.C., Koyle M.A., Swerdloff R.S., Rajfer J. (1988): Effects of cyclosporine on the hypothalamic-pituitary-gonadal axis in the male rat: mechanism of action. Endocrinology, 123, 1069–1074.CrossRefPubMedGoogle Scholar
  27. 27.
    Nieszporek T., Grzeszczak W., Kokot F., Zukowska-Szczechowska E., Kusmierski S., Szkodny A. (1989): Influence of type of immunosuppressive therapy on secretion of somatotropin and function of the pituitary-adrenal and pituitary-gonadal axis in patients with a kidney transplant. Nephron, 53, 65–69.CrossRefPubMedGoogle Scholar
  28. 28.
    Ramirez G., Narvarte J., Bittle P.A., Ayers-Chastain C., Dean S.E. (1991): Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron, 58, 27–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Esquifino A.I., Moreno M.L., Agrasal C., Villanua M.A. (1995): Effects of cyclosporine on ovarian function in sham-operated and pituitary-grafted young female rats. Proc. Soc. Exp. Biol. Med., 208, 397–403.PubMedGoogle Scholar
  30. 30.
    Hirasawa K., Enosawa S. (1990): Effects of sex steroid hormones on sex-associated differences in the survival time of allogeneic skin grafts in rats. Transplantation, 50, 637–641.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • P. A. Kelly
    • 3
    • 2
  • H. Wang
    • 1
  • K. L. Napoli
    • 3
  • B. D. Kahan
    • 3
  • H. W. Strobel
    • 1
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of Texas-Houston Health Science CenterHoustonUSA
  2. 2.College of PharmacyUniversity of HoustonHoustonUSA
  3. 3.Division of Immunology and Organ TransplantationUT-Houston Medical SchoolHoustonUSA

Personalised recommendations